China Vaccine Market Forecasts To 2027: Pneumococcal, Meningococcal Meningitis, And DTP Vaccines Controls Significant Portion Of China Vaccines Industry

(MENAFN- GlobeNewsWire - Nasdaq)

Dublin, March 07, 2023 (GLOBE NEWSWIRE) -- The 'china vaccine market, size, forecast 2023-2027, industry trends, growth, impact of inflation, opportunity company analysis' report has been added to ResearchAndMarkets.com's offering.
The Chinese Vaccine Market will surpass US$ 12.16 Billion by 2027 at a CAGR of 11.97 Percent according to the publisher. Annually in China, approx. 700 million vaccine doses are produced; China is one of the world's largest producers of vaccines.

As a result, China has drawn significant attention to the vaccine industry to play a representative role. In addition, it is a closed market with a solid local vaccine industry, access to which is challenging for Western players.
Category 1 & 2 Vaccines in China
In China, Vaccines are available through the government's Expanded Program on Immunization (EPI) at no charge for aged 14 years of children. These government-purchased vaccines are called Category 1 under the Regulations on the Administration of Vaccines and Vaccination.

In contrast, private-sector also known as Category 2 vaccines, such as rabies vaccine, influenza vaccine (InfV), and Haemophilus influenza type b vaccine (Hib), are available but are usually paid for out-of-pocket, as they are included in neither the EPI system nor government health insurance. According to our research findings, the China Vaccine market was US$ 6.91 Billion in 2022.
Disease Type: Pneumococcal, Meningococcal Meningitis, and DTP Vaccines Controls Significant Portion of China Vaccines Industry
Meningococcal Meningitis, Pneumococcal, and DTP Vaccine market are expected to control a significant portion of China's vaccine market. The vaccine market in China is segmented into Meningococcal meningitis, Pneumococcal, DTP, Ebola, Rabies & Others. In Aug 2021, China formally revised its laws to allow parents to have up to three children to boost the birth rate.

In part, thanks to the loosening of the second-child policy in China, the number is expected to increase. China's vaccine industry has always been more petite and less mature than it's US, European, or Indian counterparts. However, over the past decades, it has rapidly grown to become one of the only developing countries able to manufacture and supply most vaccines used in its domestic immunization program.
Product Insight: PCV13 has Highest Share in the Chinese Vaccine Industry
In terms of products, the Products included in this report are as follows: MCV4, MPSV4, MCV2-Hib, MCV2, MPSV2 and Men A, PCV13, and PPV23. PCV13 holds the maximum share of the China vaccine market. Therefore, it is predicted that PCV13 will also maintain its top place during the forecasting period. In addition, China is the most prominent vaccine consumer in the world. As a result, Chinese residents have become much more aware of preventive health care due to its impact, which has also driven the vaccination rate.
Key Company Insights
The major players covered in the report are Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd.

In addition, the R&D, clinical, and commercialization experience accumulated by the COVID-19 vaccine would help a group of outstanding domestic Chinese vaccine company's snowball. Against this backdrop, the Chinese vaccine industry is expected to usher in a golden period. The next decade will be for China's biopharmaceuticals to move from catching up to surpassing a 'golden decade' for the Chinese vaccine industry.
May 2022, Walvax Biotechnology Co., Ltd. announced the results for the immunogenicity and safety profile of PCV13, the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, administered as an infant series at 3, 4, and 5 months of age and a booster dose at 12-15 months of age in Chinese infants as part of the randomized, multi-center, double-blind, and positive-controlled phase 3 clinical trial in China to demonstrate the non-inferior immune responses and safety of PCV13 as compared to Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM197 Protein] ('PCV7').
Key Company Covered

  • Sinopharm Group (China National Biotec Group Company Limited)
  • Hualan Biological Engineering Inc
  • Chongqing Zhifei Biological Products Co Ltd
  • Walvax Biotechnology Co Ltd
  • Beijing Tiantan Biological Products Corp Ltd
  • Sinovac Biotech
  • Shenzhen Kangtai Biological Products Co Ltd

    Key Attributes:

  • Report Attribute Details
    No. of Pages 170
    Forecast Period 2022 - 2027
    Estimated Market Value (USD) in 2022 $6.91 Billion
    Forecasted Market Value (USD) by 2027 $12.16 Billion
    Compound Annual Growth Rate 11.9%
    Regions Covered China

    Key Topics Covered:
    1. Introduction
    2. Research & Methodology
    3. Executive Summary
    4. Market Dynamics
    4.1 Growth Drivers
    4.2 Challenges
    4.3 Opportunities
    5. China Vaccine Market
    5.1 Public
    5.2 Private
    6. China Vaccine Doses
    6.1 Public
    6.2 Private
    7. China Vaccine Share Analysis
    7.1 By Sectors Market Share
    7.2 By Sectors Vaccine Doses Share
    7.3 By Products Type Market Share
    7.4 By Disease Type Market Share
    8. Meningococcal Meningitis Vaccine Market & Doses Analysis
    8.1 Meningococcal Meningitis Vaccine
    8.1.1 Public
    8.1.2 Private
    8.2 Meningococcal Meningitis Doses
    8.2.1 Public
    8.2.2 Private
    9. Pneumococcal Vaccines Market & Doses Analysis
    9.1 Pneumococcal Vaccines
    9.2 Pneumococcal Vaccines Doses
    10. DTP Vaccine Market & Doses Analysis
    10.1 DTP Vaccine Market
    10.1.1 DTaP
    10.1.2 DTcP
    10.2 DTP Vaccine Doses
    10.2.1 Public
    10.2.2 Private
    11. Rabies Vaccine Market
    12. Ebola Vaccine Market
    13. Product - China Vaccine Market
    13.1 MCV4
    13.2 MPSV4
    13.3 MCV2-Hib
    13.4 MCV2
    13.5 MPSV2 and Men A
    13.6 PCV13
    13.7 PPV23
    13.8 Others
    14. The Vaccine Regulatory Authority of China
    15. Required and Recommended Vaccinations for China Travel
    16. Mergers & Acquisitions
    17. Company Sales
    17.1 Sinopharm Group (China National Biotec Group Company Limited)
    17.1.1 Overview
    17.1.2 Recent Initiatives
    17.1.3 Net Sales
    17.2 Hualan Biological Engineering Inc
    17.2.1 Overview
    17.2.2 Recent Initiatives
    17.2.3 Net Sales
    17.3 Chongqing Zhifei Biological Products Co Ltd
    17.3.1 Overview
    17.3.2 Recent Initiatives
    17.3.3 Net Sales
    17.4 Walvax Biotechnology Co Ltd
    17.4.1 Overview
    17.4.2 Recent Initiatives
    17.4.3 Net Sales
    17.5 Beijing Tiantan Biological Products Corp Ltd
    17.5.1 Overview
    17.5.2 Recent Initiatives
    17.5.3 Net Sales
    17.6 Sinovac Biotech
    17.6.1 Overview
    17.6.2 Recent Initiatives
    17.6.3 Net Sales
    17.7 Shenzhen Kangtai Biological Products Co Ltd
    17.7.1 Overview
    17.7.2 Recent Initiatives
    17.7.3 Net Sales

    For more information about this report visit

    About ResearchAndMarkets.com
    ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


    • chinese vaccine market

    Chinese Vaccine Market Chinese Vaccine Market Tags covid19 vaccine ebola vaccine immunization influenza vaccine pneumococcal vaccine rabies vaccine vaccines vaccines companies


    Legal Disclaimer:
    MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.